Menu
Contacts

01

Who we are

02

Research & Innovation

04

MyGeneraTM

03

Product Pipeline

06

Partnership

05

News & Media

A new era of DNA drugs for precision medicine

Biogenera is developing a new generation of DNA-based drugs for precision medicine to treat currently incurable diseases. Thanks to an innovative approach that acts directly on diseased genes, we aim to save the lives of those facing aggressive tumors and other serious conditions.

Read more

A new era of DNA drugs for precision medicine

Biogenera is developing a new generation of DNA-based drugs for precision medicine to treat currently incurable diseases. Thanks to an innovative approach that acts directly on diseased genes, we aim to save the lives of those facing aggressive tumors and other serious conditions.

Read more

DNA-based drugs for precision medicine

BIOGENERA SpA is a company operating in the pharmaceutical biotechnology sector, specializing in the research and development of new personalized DNA-based biotechnological drugs for the treatment of serious diseases.

Founded in 2008 and based in Bologna, BIOGENERA SpA is an innovative small to medium-sized enterprise (innovative SME) that relies on a multidisciplinary team of researchers and collaborates with numerous partners, including universities (particularly the University of Bologna) and companies in the pharmaceutical sector.

01

A New Approach
to Treatment

Our drugs switch off the mutated genes responsible for diseases, acting directly on the DNA to stop the progression of the illness.

02

MyGenera™:
Revolutionary Technology

The patented platform MyGenera™ rapidly identifies anti-gene oligonucleotides capable of selectively targeting diseased genes.

Read more

03

BGA002: Therapy for Pediatric Tumors

BGA002 works by switching off the MYCN gene, the main driver of aggressive childhood tumors, through a precise and safe action.

04

Pipeline: The Future of Gene Therapy

In addition to BGA002, we are working on new gene therapies for resistant tumors and rare diseases, expanding treatment possibilities.

Read more

05

Partnerships and Collaborations

Biogenera collaborates with pharmaceutical companies and investors to accelerate drug development and bring innovation to patients.

News & Events

June 24, 2024

Agreement signed with CVBF for phase I clinical trial of new anti-cancer drug BGA002 – last days to invest in BIOGENERA SpA on Mamacrowd

BIOGENERA SpA has officially signed an agreement with CVBF (Consortium for Biological and Pharmacological Evaluations) to monitor and execute the phase I clinical trial of the new drug BGA002, intended for the treatment of aggressive pediatric cancers associated with alterations in the MYCN tumor gene.
Read more

June 19, 2024

Funding from European Community approved for collaborative research program between BIOGENERA SpA and University of Padua

Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua.
Read more

June 11, 2024

New operating unit of BIOGENERA SpA in Paris in the prestigious Paris Saclay Cancer Cluster (PSCC)

The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif area, and is the first oncology cluster in France, recognized as an international excellence. The PSCC promotes collaboration among scientific, medical and industrial communities internationally, providing access to cutting-edge resources and treatments.
Read more

June 6, 2024

A New Goal for Biogenera: BGA002, the Future of Cancer Therapy

Il team di Biogenera ha raggiunto un risultato fondamentale nello sviluppo dell’ innovativo farmaco anti-tumorale BGA002: un farmaco rivoluzionario che si concentra su tumori aggressivi sia nei bambini che negli adulti, colpendo specificamente le cellule tumorali e risparmiando quelle sane.
Read more

February 21, 2024

BIOGENERA will participate in the Bio Europe Spring in Barcelona

Building on the success of EBD Group’s flagship conference, BIO-Europe®, BIO-Europe Spring will bring together more than 3,700 top executives from around the world. More than 20,000 meetings of potential partnerships will take place to connect leaders in academia, start-ups and growing biotechnology companies with forward-looking investors and pharmaceutical companies.
Read more

June 20, 2023

NewCap is chosen as the new investor relations firm for BIOGENERA

È stato siglato un accordo con NewCap, società francese di Investor Relation, la quale si occuperà della gestione delle comunicazioni ufficiali di BIOGENERA SpA a partire dalla quotazione in borsa su Euronext di Parigi.
Read more

Company

Useful Links

Contacts

Address: Via dell’Artigianato 2, 40064 – Ozzano dell’Emilia (BO) – ITALY

Phone: +39 051 0218311

E-Mail: info@biogenera.com

BIOGENERA SpA - Copyright 2025

en_USEnglish
it_ITItalian en_USEnglish